entertainment -WSS

entertainment

author：entertainment 2025-09-30 15:16:50 - browse：1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Charles Manson follower Leslie Van Houten released from prison after 53 years

focus

WSS

Beach reads and more: STAT's 2023 summer book list

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Leqembi, other new Alzheimer’s drugs require better biomarkers

'Patient friction coefficient' can gauge a clinical trial's patient burden

Medical devices makers are asking for forgiveness, not permission

Erich Jarvis studies song birds to learn about human stuttering

focus

entertainment

hotspot

Virginia high school admissions case could be legal follow

Yancopoulos of Regeneron works to expand Dupixent success

In Memoriam: Notable people who died in 2023

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Wildfire smoke exposes gaps in outdoor worker protections

Testing GLP

Heart attack and stroke risk calculators need revising

HCA discloses massive data breach affecting 11 million patients

Trump demands the U.S. pay no more for drugs than other countries … again

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

hotspot

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Iowa House, Senate pass 6

Mirador, a new biotech startup, launches with $400 million

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Oak trusses raised to roof of fire

Study: Pain burden is higher in Black NFL players than white ones

focus

Wikipedia

focus

leisure time